[go: up one dir, main page]

WO2000027994A3 - Chlamydia pneumoniae genome sequence - Google Patents

Chlamydia pneumoniae genome sequence Download PDF

Info

Publication number
WO2000027994A3
WO2000027994A3 PCT/US1999/026923 US9926923W WO0027994A3 WO 2000027994 A3 WO2000027994 A3 WO 2000027994A3 US 9926923 W US9926923 W US 9926923W WO 0027994 A3 WO0027994 A3 WO 0027994A3
Authority
WO
WIPO (PCT)
Prior art keywords
genome sequence
expression
pneumoniae genome
chlamydia pneumoniae
pneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/026923
Other languages
French (fr)
Other versions
WO2000027994A2 (en
Inventor
Richard Stephens
Wayne Mitchell
Sue Kalman
Ronald Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to CA002350775A priority Critical patent/CA2350775A1/en
Priority to EP99960323A priority patent/EP1133572A4/en
Priority to JP2000581161A priority patent/JP2002529069A/en
Priority to AU17223/00A priority patent/AU1722300A/en
Publication of WO2000027994A2 publication Critical patent/WO2000027994A2/en
Publication of WO2000027994A3 publication Critical patent/WO2000027994A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

C. pneumoniae genome sequence and analysis of the encoded polypeptides and RNAs are provided. The C. pneumoniae gene nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.
PCT/US1999/026923 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence Ceased WO2000027994A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002350775A CA2350775A1 (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence
EP99960323A EP1133572A4 (en) 1998-11-12 1999-11-12 GENOME SEQUENCE OF CHLAMYDIA PNEUMONIAE
JP2000581161A JP2002529069A (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence
AU17223/00A AU1722300A (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10827998P 1998-11-12 1998-11-12
US12860699P 1999-04-08 1999-04-08
US60/128,606 1999-04-08
US60/108,279 1999-04-08

Publications (2)

Publication Number Publication Date
WO2000027994A2 WO2000027994A2 (en) 2000-05-18
WO2000027994A3 true WO2000027994A3 (en) 2000-11-23

Family

ID=26805735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026923 Ceased WO2000027994A2 (en) 1998-11-12 1999-11-12 Chlamydia pneumoniae genome sequence

Country Status (5)

Country Link
EP (1) EP1133572A4 (en)
JP (1) JP2002529069A (en)
AU (1) AU1722300A (en)
CA (1) CA2350775A1 (en)
WO (1) WO2000027994A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108514870A (en) * 2018-04-27 2018-09-11 湖南大学 Hydrotalcite-poly m-phenylene diamine composite material and preparation method and application

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0909323T3 (en) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori bacterioferritin
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1135501A1 (en) 1998-12-01 2001-09-26 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
HK1044020B (en) 1998-12-08 2008-10-31 科里克萨有限公司 Compounds and methods for treatment and diagnosis of chlamydialinfection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000039158A1 (en) 1998-12-23 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE384738T1 (en) 1998-12-28 2008-02-15 Aventis Pasteur CHLAMYDIA ANTIGENS, CORRESPONDING DNA FRAGMENTS AND THEIR USES
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1163342B1 (en) 1999-03-12 2008-12-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU3767300A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 47 human secreted proteins
AU4023200A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
CA2373021A1 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP4667694B2 (en) 1999-09-20 2011-04-13 サノフィ、パストゥール、リミテッド Chlamydia antigen and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU784193B2 (en) 1999-12-22 2006-02-16 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2407114A1 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60125350T2 (en) 2000-05-08 2007-07-12 Sanofi Pasteur Ltd., Toronto CHLAMYDIA ANTIGENES, CORRESPONDING DNA FRAGMENTS AND ITS USES
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
EP2277896A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
LT2395073T (en) 2002-11-01 2017-11-10 Glaxosmithkline Biologicals S.A. Drying process
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ES2328697T5 (en) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
ATE552267T1 (en) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic IMMUGENES OF UROPATHOGENS ESCHERICHIA COLI
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2010500399A (en) 2006-08-16 2010-01-07 ノバルティス アーゲー Immunogen from Urinary Pathogenic Escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0816689B1 (en) 2007-09-12 2021-08-24 Novartis Ag VACCINE COMPOSITION, KIT AND METHOD FOR MAKING A VACCINE COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFECTION BY STREPTOCOCCUS PYOGENES
BRPI0821240B8 (en) 2007-12-21 2022-10-04 Novartis Ag mutant forms of streptolysin o
EP2349520B1 (en) 2008-10-27 2016-05-25 GlaxoSmithKline Biologicals SA Purification method for carbohydrate from group a streptococcus
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
US20110293664A1 (en) * 2008-12-17 2011-12-01 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CA2749367A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
RU2011140508A (en) 2009-03-06 2013-04-20 Новартис Аг Chlamydia antigens
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
LT2493498T (en) 2009-10-30 2017-05-25 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
AU2011316924A1 (en) * 2010-10-20 2013-05-02 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
CN107837394A (en) 2011-06-24 2018-03-27 埃皮托吉尼西斯有限公司 Pharmaceutical composition as the combination of the carrier comprising selection of antigen specific immune conditioning agent, vitamin, tannin and flavonoids
CN103917245B (en) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 Method for preparing glycoprotein glycoconjugate
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
CA2874210A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374718A (en) * 1992-08-26 1994-12-20 Gen-Probe Incorporated Nucleic acid probes to chlamydia pneumoniae

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08294400A (en) * 1995-04-28 1996-11-12 Hitachi Chem Co Ltd Probe and primer for detecting and measuring chlamydia pneumoniae gene, detection and measurement of chlamydia pneumoniae gene using the same probe or primer and reagent for detecting and measuring chlamydia pneumoniae gene containing the same probe or primer
JPH10210978A (en) * 1997-01-31 1998-08-11 Hitachi Chem Co Ltd Recombinant vector and transformant containing the same, and recombinant vacurovirus and its production, and production of chlamydia pneumoniae antigen polypeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374718A (en) * 1992-08-26 1994-12-20 Gen-Probe Incorporated Nucleic acid probes to chlamydia pneumoniae
US5683870A (en) * 1992-08-26 1997-11-04 Gen-Probe Incorporated Nucleic acid probes to Chlamydia pneumoniae

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108514870A (en) * 2018-04-27 2018-09-11 湖南大学 Hydrotalcite-poly m-phenylene diamine composite material and preparation method and application
CN108514870B (en) * 2018-04-27 2020-02-28 湖南大学 Hydrotalcite-polym-phenylenediamine composite material and its preparation method and application

Also Published As

Publication number Publication date
WO2000027994A2 (en) 2000-05-18
CA2350775A1 (en) 2000-05-18
EP1133572A2 (en) 2001-09-19
JP2002529069A (en) 2002-09-10
AU1722300A (en) 2000-05-29
EP1133572A4 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2000027994A3 (en) Chlamydia pneumoniae genome sequence
WO2002014358A3 (en) Novel secreted proteins and their uses
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
EP0804609A4 (en) NOVEL p53 RESPONSE GENES
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
WO1999057282A3 (en) Pesticidal toxins and nucleotide sequences which encode these toxins
WO2000008157A3 (en) Human anion transporter genes atnov
WO2000009693A3 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
CA2336261A1 (en) Cyclin e2 genes and proteins
WO1998011234A3 (en) Human protein kinases
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
WO2002032939A3 (en) Secreted proteins and their uses
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2002026801A3 (en) Secreted proteins and their uses
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2002064827A3 (en) Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof
WO2000058464A3 (en) Rab genes and their uses
WO2001036478A3 (en) Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides
EP1383871A4 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
EP1383877A4 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
EP1383908A4 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
EP1385991A4 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2005049818A3 (en) Genes encoding human deubiquitinating enzymes
WO1998012220A3 (en) Novel tumor proteins
WO2004013281A3 (en) Novel proteins and their uses

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17223

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2350775

Country of ref document: CA

Ref country code: CA

Ref document number: 2350775

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581161

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999960323

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999960323

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999960323

Country of ref document: EP